A specific gene expression signature for visceral organ metastasis in breast cancer

por Savci-Heijink, C. D., Halfwerk, H., Koster, J., Horlings, H. M., van de Vijver, M. J.
Publicado 2019

Epithelial-to-mesenchymal transition status of primary breast carcinomas and its correlation with metastatic behavior

por Savci-Heijink, C. D., Halfwerk, H., Hooijer, G. K. J., Koster, J., Horlings, H. M., Meijer, S. L., van de Vijver, M. J.
Publicado 2019

High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites

por Kraan, W, Horlings, H M, van Keimpema, M, Schilder-Tol, E J M, Oud, M E C M, Scheepstra, C, Kluin, P M, Kersten, M J, Spaargaren, M, Pals, S T
Publicado 2013

Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer

por Nederlof, I., Hajizadeh, S., Sobhani, F., Raza, S. E. A., AbdulJabbar, K., Harkes, R., van de Vijver, M. J., Salgado, R., Desmedt, C., Kok, M., Yuan, Y., Horlings, H. M.
Publicado 2022

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer

por Liefaard, M. C., van der Voort, A., van Ramshorst, M. S., Sanders, J., Vonk, S., Horlings, H. M., Siesling, S., de Munck, L., van Leeuwen, A. E., Kleijn, M., Mittempergher, L., Kuilman, M. M., Glas, A. M., Wesseling, J., Lips, E. H., Sonke, G. S.
Publicado 2023

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial

por Geurts, V.C.M., Voorwerk, L., Balduzzi, S., Salgado, R., Van de Vijver, K., van Dongen, M.G.J., Kemper, I., Mandjes, I.A.M., Heuver, M., Sparreboom, W., Haanen, J.B.A.G., Sonke, G.S., Horlings, H.M., Kok, M.
Publicado 2023